Topics:
Gastrointestinal Cancers • Medical Oncology
Are you considering the use of circulating tumor DNA or circulating tumor cell count to make clinical decisions in the adjuvant setting after colon cancer resection?
Has the new data with the Natera assay from Reinert T et al in JAMA Oncology May 2019 changed your practice?
Answer from: Medical Oncologist at Academic Institution
Circulating tumor DNA (ctDNA) has become commercially available with several NGS panel sequencing 70-100 genes. It is somewhat of interest in determining resistance to anti-EGFR drugs for advanced disease patients, as transient RAS mutations may emerge and then recede.In the adjuvant setting, one st...
Sign in or Register to read more